LIAN - Despite FDA approval for heart condition drug mavacamten LianBio stock falls 24%

Shares of LianBio (NASDAQ:LIAN) are down 24% in Friday afternoon trading even as the company and partner Bristol-Myers Squibb (BMY) this morning won approval for the hypertrophic cardiomyopathy drug Camzyos (mavacamten). One of the reasons for the decline could be that the approval came with a boxed warning for the risk of heart failure on the label and access is restricted through a Risk Evaluation and Mitigation Strategy program. As a result, patients must comply with monitoring requirements. Check out Seeking Alpha contributor Bhavneesh Sharma's assessment of LianBio (LIAN).

For further details see:

Despite FDA approval for heart condition drug mavacamten, LianBio stock falls 24%